A Phase 1/2 interventional study of SD-101 and Radiation therapy in B-cell Lymphoma, sponsored by Dynavax Technologies Corporation. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-04.
Sponsored by Dynavax Technologies Corporation (part of Sanofi) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 398 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.
Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 225th largest by enrollment of the 380 interventional ones that give a count, is one of 10 that started in 2014, is one of 75 in phase 1/2, and was the 125th registered.
885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.
Browse Lymphoma, B-Cell studies →91 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:
Umoja Biopharma · Sites in United States
Ages 18+
Nurix Therapeutics, Inc. · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Paolo Caimi, MD · Sites in United States
Ages 18+
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
398 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 236 · Phase 2 188 · Phase 3 23 · Phase 4 1
First in 1991; this study’s year is marked. 10 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.
Median enrollment 37 across the 380 interventional studies, 150 across the 17 observational. Of the 217 that completed or were terminated, 111 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
176 of 398 have an industry lead sponsor. The 10 most frequent:
This study is registered under Dynavax Technologies Corporation, one of the names counted as Sanofi. Under that name alone:
Dynavax Technologies Corporation is the lead sponsor of 25 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.
Sanofi has 3 studies filed under Lymphoma, B-Cell — fewer than ten, so there is no comparison to draw.
52 of the studies in Lymphoma, B-Cell with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT04759586Phase 3National Cancer Institute (NCI)Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | 2027-06-30 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT06047080Phase 3Hoffmann-La RocheAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | 2027-10-01 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
Add all 52 to your calendar (.ics) → With an account.
Among the 398 studies in Lymphoma, B-Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the safety and tolerability of escalating doses of SD-101 in combination with localized low-dose radiation therapy in adult subjects with untreated low-grade B-cell lymphoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PART 1 * Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1 * COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29 * COHORT 2: 2 mg/mL at Days 1, 8, 15, 22, and 29 * COHORT 3: 4 mg/mL at Days 1, 8, 15, 22, and 29 * COHORT 4: 8 mg/mL at Days 1, 8, 15, 22, and 29 PART 2 Cycle 1: Required * Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1 * COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29 * COHORT 2: 8 mg/mL at Days 1, 8, 15, 22, and 29 Cycle 2: Optional * Radiation: 2 fractions of 2 Gy over 2 days at Days 180 and 181 * COHORT 1: 1 mg/mL at Days 181, 188, 195, 202, and 209 * COHORT 2: 8 mg/mL at Days 181, 188, 195, 202, and 209
Drug: SD-101 · Radiation: Radiation therapy
Number of Participants Experiencing Dose-limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD).
Time frame: Up to Day 36
Number of Participants Experiencing Injection-site Reactions (ISRs)
Injection site reaction 1 = Redness, Injection site reaction 2 = Swelling, Injection site reaction 3 = Pain
Time frame: Up to Day 36
Number of Participants Experiencing Serious Adverse Events (SAEs)
Time frame: Up to 38 weeks
Pharmacodynamic Profile - Expression of IFN-responsive Genes (GBP-1, ISG-54, MCP-1, and MxB)
Fold change of IFN-responsive gene expression relative to Day 8
Time frame: Change from Day 8 to Day 9
Number of Participants With Preliminary Response - Local (Injected Lesions)
Subjects with maximum decrease of 50% or greater in sum of products of diameters of lesions.
Time frame: Up to 38 weeks
Number of Participants With Preliminary Response - Systemic (Non-injected Lesions)
Subjects with maximum decrease of 50% or greater in sum of products of diameters of lesions.
Time frame: Up to 38 weeks
| Milestone | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL |
|---|---|---|---|---|
| Started | 3 | 3 | 3 | 4 |
| Completed | 2 | 0 | 0 | 0 |
| Not completed | 1 | 3 | 3 | 4 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 1 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 3 |
| Withdrew: Other | 1 | 1 | 0 | 0 |
| Milestone | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL |
|---|---|---|---|---|
| Started | 7 | 0 | 0 | 9 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 7 | 0 | 0 | 9 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 6 | 0 | 0 | 8 |
| participants | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL |
|---|---|---|---|---|
| Number of Participants Experiencing Dose-limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD). | 0 | 0 | 0 | 0 |
Injection site reaction 1 = Redness, Injection site reaction 2 = Swelling, Injection site reaction 3 = Pain
| Participants | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL |
|---|---|---|---|---|
| Injection site reaction 1 | 4 | 0 | 1 | 5 |
| Injection site reaction 2 | 4 | 1 | 2 | 2 |
| Injection site reaction 3 | 7 | 3 | 1 | 6 |
| participants | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL |
|---|---|---|---|---|
| Renal and urinary disorders | 0 | 0 | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders | 0 | 0 | 1 | 0 |
| Total # of participants with SAEs | 0 | 0 | 1 | 1 |
Fold change of IFN-responsive gene expression relative to Day 8
| Fold Change | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL |
|---|---|---|---|---|
| Pharmacodynamic Profile - Expression of IFN-responsive Genes (GBP-1, ISG-54, MCP-1, and MxB) | 7.42 ± 4.78 | 8.06 ± 2.05 | 9.89 ± .59 | 7.78 ± 7.54 |
Subjects with maximum decrease of 50% or greater in sum of products of diameters of lesions.
| Participants | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL |
|---|---|---|---|---|
| Number of Participants With Preliminary Response - Local (Injected Lesions) | 6 | 3 | 1 | 8 |
Subjects with maximum decrease of 50% or greater in sum of products of diameters of lesions.
| Participants | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL |
|---|---|---|---|---|
| Number of Participants With Preliminary Response - Systemic (Non-injected Lesions) | 2 | 0 | 0 | 2 |
Collected over Up to 38 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1 mg/mL | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| 2 mg/mL | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| 4 mg/mL | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| 8 mg/mL | 0/13 (0%) | 1/13 (7.7%) | 13/13 (100%) |
| Event | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL |
|---|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/10 | 0/3 | 1/3 | 0/13 |
| Focal segmental glomerulosclerosisRenal and urinary disorders | 0/10 | 0/3 | 0/3 | 1/13 |
| Event | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL |
|---|---|---|---|---|
| ChillsGeneral disorders | 8/10 | 2/3 | 3/3 | 13/13 |
| FatigueGeneral disorders | 8/10 | 3/3 | 3/3 | 12/13 |
| MalaiseGeneral disorders | 9/10 | 2/3 | 3/3 | 13/13 |
| MyalgiaMusculoskeletal and connective tissue disorders | 7/10 | 3/3 | 3/3 | 13/13 |
| HeadacheNervous system disorders | 8/10 | 3/3 | 3/3 | 11/13 |
| PyrexiaGeneral disorders | 4/10 | 1/3 | 2/3 | 12/13 |
| NasopharyngitisInfections and infestations | 1/10 | 2/3 | 0/3 | 1/13 |
| NauseaGastrointestinal disorders | 2/10 | 1/3 | 0/3 | 8/13 |
| Injection Site ErythemaGeneral disorders | 4/10 | 0/3 | 1/3 | 3/13 |
| VomitingGastrointestinal disorders | 0/10 | 1/3 | 0/3 | 5/13 |
Intent-to-treat population
| Age, Categorical(Participants) | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 2 | 2 | 7 | 18 |
| >=65 years | 3 | 1 | 1 | 6 | 11 |
| Age, Continuous(years) | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL | Total |
|---|---|---|---|---|---|
| Mean | 56.9 ± 13.53 | 56 ± 9.54 | 61 ± 16.52 | 62.7 ± 12.32 | 59.8 ± 12.59 |
| Sex: Female, Male(Participants) | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL | Total |
|---|---|---|---|---|---|
| Female | 4 | 2 | 1 | 6 | 13 |
| Male | 6 | 1 | 2 | 7 | 16 |
| Ethnicity (NIH/OMB)(Participants) | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 3 | 3 | 13 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 8 | 3 | 3 | 12 | 26 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 | 2 |
| Region of Enrollment(Participants) | 1 mg/mL | 2 mg/mL | 4 mg/mL | 8 mg/mL | Total |
|---|---|---|---|---|---|
| United States | 10 | 3 | 3 | 13 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Oct 2014, a primary completion of Apr 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2020, 3 years 5 months after primary completion. A results delay was requested in Mar 2020.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nelitolimod
Dynavax Technologies Corporation →